by Peter Ciszewski | Sep 14, 2017
After being diagnosised with polycythemia vera (PV), David Gelly finds himself on a new journey. In this video, he explains his diagnosis of PV—one of a group of rare, chronic blood cancers known as myeloproliferative neoplasms (MPNs). MPNs are rare, chronic blood...
by Peter Ciszewski | Sep 6, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses emerging treatment options for patients suffering from X-linked retinoschisis (XLRS)....
by Peter Ciszewski | Sep 5, 2017
Insmed announced top-line data from its Phase 3 CONVERT study. The global CONVERT study met its primary endpoint of culture conversion by Month 6 with statistical and clinical significance. The study demonstrated that the addition of ALIS to guideline-based therapy...
by Peter Ciszewski | Aug 28, 2017
With today’s $12 billion purchase of Santa Monica-based Kite Pharma, Gilead has not only validated the CAR-T industry, but also put a price on what the technology is worth. With their product likely to new approved by November, Kite has been recognized as an industry...
by Peter Ciszewski | Aug 27, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses X-Linked Retinoschisis (XLRS). X-linked retinoschisis (XLRS) is an inherited early onset...
